ライフサイエンスコーパス: parainfluenza virus

1 rus, rhinovirus, and influenza virus but not parainfluenza virus.

2 p of viruses that includes measles virus and parainfluenza viruses.

3 an respiratory syncytial virus and the human parainfluenza viruses.

4 tein subunits play the cell entry concert of parainfluenza viruses.

5 detects influenza A virus (Flu-A) and Flu-B, parainfluenza virus 1 (PIV-1), PIV-2, and PIV-3, and res

6 l virus (RSV), human metapneumovirus (HMPV), parainfluenza virus 1 to 3 (PIV1, PIV2, and PIV3), and a

7 FilmArray RP detected more parainfluenza viruses 1 and 3 than ProParaflu+ (18 versu

8 viruses, respiratory syncytial virus (RSV), parainfluenza viruses 1 to 3, and adenovirus (DAKO Diagn

9 virus, influenza A virus, influenza B virus, parainfluenza viruses 1 to 3, and respiratory syncytial

10 nfluenza A virus H1-2009, influenza B virus, parainfluenza viruses 1 to 4, respiratory syncytial viru

11 syncytial virus; influenza A and B viruses; parainfluenza viruses 1, 2, 3, and 4; human metapneumovi

12 an respiratory syncytial virus (HRSV); human parainfluenza viruses 1, 2, and 3 (HPIV1, -2, and -3, re

13 piratory syncytial virus, influenza A and B, parainfluenza viruses 1-3, and adenovirus.

14 picornaviruses, coronaviruses 229E and OC43, parainfluenza viruses 1-3, influenza viruses AH1, AH3, a

15 in reaction for respiratory syncytial virus, parainfluenza viruses 1-4, influenza A and B, human meta

16 ramyxoviruses simian virus 5 (SV5) and human parainfluenza virus 2 (HPIV2) overcome IFN-alpha/beta re

17 hese are encoded by mumps virus (MuV), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5

18 Simian virus 5 (SV5) targets STAT1, human parainfluenza virus 2 targets STAT2, and mumps virus tar

19 ith respiratory syncytial virus (RSV), human parainfluenza virus 3 (HPIV-3), and influenza virus on t

20 We previously reported that a human parainfluenza virus 3 (HPIV3) F peptide effectively inhi

21 described for a cluster of 12 cases of human parainfluenza virus 3 (HPIV3) infection that occurred am

22 titatively influence fusion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations

23 yxoviruses, such as Nipah virus (NiV), human parainfluenza virus 3 (HPIV3), measles virus (MeV), mump

24 Parainfluenza virus 3 (PIV-3) infection is highly restri

25 The majority of this decrease was in parainfluenza virus 3 (PIV3) (8.3% to 2.2%, P < .001).

26 c fibrosis patients; however, its use during parainfluenza virus 3 (PIV3) infection has not been eval

27 The secreted human parainfluenza virus 3 F forms a trimer with distinct hea

28 However, we found that a human parainfluenza virus 3 F-peptide is more effective at inh

29 eaved ectodomain of the paramyxovirus, human parainfluenza virus 3 fusion (F) protein, a member of th

30 homologous HN protein, as well as NDV-human parainfluenza virus 3 HN chimeras.

31 ection but similar to that for influenza and parainfluenza virus 3 infection in all age groups.

32 mumps virus, Newcastle disease virus, human parainfluenza virus 3, and Nipah virus.

33 Antibody titers to RSV, human parainfluenza virus 3, measles, and influenza H1N1, H3N2

34 cell lines with Sendai virus (SeV) or human parainfluenza virus 3, two prototypic paramyxoviruses, c

35 dence similar to that of influenza virus and parainfluenza virus 3.

36 on of 274 of 279 influenza viruses, 33 of 38 parainfluenza viruses, 35 of 51 adenoviruses, and 52 of

37 Putative viral pathogens included human parainfluenza virus 4 (aOR 9.3, P = .12), human bocaviru

38 rus [EV], 118; bocavirus, 8; coronavirus, 7; parainfluenza virus 4, 4; Mycoplasma pneumoniae, 1).

39 lture (metapneumovirus, coronaviruses [CoV], parainfluenza viruses 4a and 4b, and rhinoviruses) and t

40 hat Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix

41 Parainfluenza virus 5 (PIV5) activates and is neutralize

42 For the paramyxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP inter

43 Proline substitution in this region of HN of parainfluenza virus 5 (PIV5) and Newcastle disease virus

44 In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/

45 The paramyxovirus parainfluenza virus 5 (PIV5) enters cells by fusion of t

46 igh similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural

47 Because only the prefusion structure of the parainfluenza virus 5 (PIV5) F-trimer is available, to s

48 MR spectroscopy, we show that the TMD of the parainfluenza virus 5 (PIV5) fusion protein adopts lipid

49 Parainfluenza virus 5 (PIV5) HN exists as a noncovalent

50 Parainfluenza virus 5 (PIV5) is a member of the Paramyxo

51 Parainfluenza virus 5 (PIV5) is a promising viral vector

52 Parainfluenza virus 5 (PIV5) is a prototypical paramyxov

53 Parainfluenza virus 5 (PIV5) is an appealing vector for

54 Parainfluenza virus 5 (PIV5) is an enveloped, single-str

55 The P protein of parainfluenza virus 5 (PIV5) is an essential cofactor of

56 Parainfluenza virus 5 (PIV5) is thought to contribute to

57 To investigate the role of NP protein in parainfluenza virus 5 (PIV5) particle formation, NP prot

58 In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glyco

59 serendipitously identified a viral mRNA from parainfluenza virus 5 (PIV5) that activates IFN expressi

60 Preparations of parainfluenza virus 5 (PIV5) that are potent activators

61 quence variation of 16 different isolates of parainfluenza virus 5 (PIV5) that were isolated from a n

62 unable to be recognized by measles virus and parainfluenza virus 5 (PIV5) V proteins were tested in s

63 We tested the recombinant parainfluenza virus 5 (PIV5) vectors expressing RSV glyc

64 he threonine residue at position 286 of P of parainfluenza virus 5 (PIV5) was found phosphorylated.

65 The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC u

66 rotein (prefusion form) of the paramyxovirus parainfluenza virus 5 (PIV5) WR isolate was determined.

67 Parainfluenza virus 5 (PIV5), a paramyxovirus, is not kn

68 Similar results were also observed with parainfluenza virus 5 (PIV5), a paramyxovirus, when neut

69 Here we show that vaccination with parainfluenza virus 5 (PIV5), a promising live viral vec

70 Infection by parainfluenza virus 5 (PIV5), a prototypical member of t

71 Parainfluenza virus 5 (PIV5), a prototypical paramyxovir

72 The genome of parainfluenza virus 5 (PIV5), a prototypical paramyxovir

73 V), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5 (PIV5), all members of the genus R

74 Parainfluenza virus 5 (PIV5), formerly known as simian v

75 that a porcine isolate of the paramyxovirus parainfluenza virus 5 (PIV5), known as SER, requires a l

76 The strain diversity of a rubulavirus, parainfluenza virus 5 (PIV5), was investigated by compar

77 Previously, we developed two parainfluenza virus 5 (PIV5)-based RSV vaccine candidate

78 We previously generated a parainfluenza virus 5 (PIV5)-vectored vaccine candidate

79 In this study, we evaluated two parainfluenza virus 5 (PIV5)-vectored vaccines expressin

80 f the matrix (M) protein of a paramyxovirus, parainfluenza virus 5 (PIV5).

81 -3 as a binding partner for the M protein of parainfluenza virus 5 (PIV5).

82 Similar results were also observed with parainfluenza virus 5 (PIV5).

83 he FP of the F protein of the paramyxovirus, parainfluenza virus 5 (PIV5).

84 sion (F) protein of the paramxyovirus simian parainfluenza virus 5 (SV5) promotes virus-cell and cell

85 on (F) protein from the paramyxovirus simian parainfluenza virus 5 (SV5) resulted in mutant F protein

86 ined the ability of the paramyxovirus simian parainfluenza virus 5 (SV5) to affect cell cycle progres

87 NASEK was dispensable for viruses, including parainfluenza virus 5 and Coxsackie B virus, that enter

88 ructed chimeras containing the ectodomain of parainfluenza virus 5 F (PIV5 F) and either the MPER, th

89 Here we report the crystal structure of the parainfluenza virus 5 F protein in its prefusion conform

90 ess the functional role of the paramyxovirus parainfluenza virus 5 F protein TM domain, alanine scann

91 Here, a soluble form of parainfluenza virus 5 F was triggered to refold using te

92 rystal structure of a fragment of the simian parainfluenza virus 5 fusion protein (SV5 F), revealing

93 , we show that the FP from the paramyxovirus parainfluenza virus 5 fusogenic protein, F, forms an N-t

94 ng globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable

95 usion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of

96 By modeling the crystal structure of parainfluenza virus 5 into the density, it is shown that

97 The paramyxovirus parainfluenza virus 5 mediates membrane merger through i

98 t robust maturation following infection with parainfluenza virus 5 or influenza virus.

99 this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expr

100 ed "stalk exposure model" first proposed for parainfluenza virus 5 to other paramyxoviruses and propo

101 athogens: human respiratory syncytial virus, parainfluenza virus 5, and Sendai virus.

102 A parainfluenza virus 5-vectored vaccine expressing the na

103 sequence, FPIV, important for the budding of parainfluenza virus 5.

104 recently published prefusogenic structure of parainfluenza virus 5/SV5 F places CBF(2) in direct cont

105 pproach is further demonstrated here for the parainfluenza virus, a virus which can be life threateni

106 or detecting respiratory viruses, especially parainfluenza virus and adenovirus.

107 d five in which the PLx-RVP failed to detect parainfluenza virus and one in which the detection of in

108 ow fever virus, Japanese encephalitis virus, parainfluenza virus and Sendai virus.

109 ple viruses (respiratory syncytial virus and parainfluenza virus) and multiple phenotypes.

110 tory syncytial virus, human metapneumovirus, parainfluenza virus, and influenza virus) by reverse-tra

111 nfluenza A virus, two influenza B virus, one parainfluenza virus, and six adenovirus).

112 y 90% vaccinated each year), picornaviruses, parainfluenza viruses, and coronaviruses were most commo

113 etapneumovirus, respiratory syncytial virus, parainfluenza viruses, and Haemophilus influenzae being

114 Parainfluenza viruses are a common cause of seasonal res

115 Parainfluenza viruses are known to inhibit type I interf

116 causes of lower respiratory disease like the parainfluenza viruses, as well as agents of lethal encep

117 protein and nucleocapsid sustain assembly of parainfluenza viruses at the plasma membrane.

118 ke (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as

119 Three human parainfluenza viruses bind to glycans terminating with N

120 (RSV), adenoviruses, influenza viruses, and parainfluenza viruses by use of nested polymerase chain

121 Human parainfluenza viruses cause several serious respiratory

122 Although influenza and parainfluenza viruses commonly cause respiratory tract i

123 , which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and huma

124 canine adenovirus type 2 (CAV-2), and canine parainfluenza virus (CPIV), respiratory disease was ende

125 sociation with age; especially rhinovirus or parainfluenza virus detection showed positive associatio

126 The tissue culture prevalence of parainfluenza virus during this period of time was low (

127 Our results illustrate how the particles of parainfluenza viruses efficiently accommodate cargoes of

128 Parainfluenza viruses enter host cells by fusing the vir

129 V-respiratory syncytial virus (RSV) or human parainfluenza virus (HPIV) coinfections had wheezing tha

130 The human parainfluenza virus (hPIV) hemagglutinin-neuraminidase (

131 presence of the second binding site on human parainfluenza virus (hPIV) type 1, 2, and 3 and Sendai v

132 es, Respiratory Syncytial Virus (RSV), Human Parainfluenza Virus (HPIV), and Human Metapneumovirus (h

133 (23), human herpesvirus (HHV)-6B (10), human parainfluenza virus (HPIV)-2 (3), HPIV-3 (1), and human

134 he hemagglutinin-neuraminidase (HN) of human parainfluenza viruses (hPIV) in vitro and protected mice

135 Human parainfluenza viruses (HPIVs) are a common cause of acut

136 Human parainfluenza viruses (HPIVs) are among the most common

137 glutinin-neuraminidase (HN) protein of human parainfluenza viruses (hPIVs) both binds (H) and cleaves

138 Human parainfluenza viruses (HPIVs) cause widespread respirato

139 The first step in infection by human parainfluenza viruses (HPIVs) is binding to the surface

140 The paramyxoviruses, including human parainfluenza viruses (HPIVs), cause a large share of th

141 ndications that the pleomorphic particles of parainfluenza viruses incorporate multiple genomes.

142 infected cells (Wake Forest strain of Canine parainfluenza virus) induced IL-8 secretion by a mechani

143 tudies we tested the role of CD8+ T cells in parainfluenza virus-induced hyperreactivity and M2R dysf

144 While type II human parainfluenza virus induces STAT2 degradation, simian vi

145 Analysis of parainfluenza virus infection in mice revealed an unexpe

146 We used mouse models of influenza and parainfluenza virus infection to show that intranasally

147 uenza virus, respiratory syncytial virus, or parainfluenza virus infection.

148 in mixed bone marrow chimeric mice during a parainfluenza virus infection.

149 central memory subpopulations to intranasal parainfluenza virus infection.

150 ccine nor clinically effective treatment for parainfluenza virus infection.

151 Parainfluenza virus infections did not differentially af

152 to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin

153 ools elicited by nonpersistent influenza and parainfluenza virus infections.

154 iratory syncytial virus, 2 adenovirus, and 1 parainfluenza virus infections.

155 ents with respiratory syncytial virus (RSV), parainfluenza virus, influenza virus, metapneumovirus (M

156 Parainfluenza viruses initiate infection by binding to c

157 t for lower-respiratory-tract infection with parainfluenza virus; it stabilized during the months aft

158 mouse model in which infection with a mouse parainfluenza virus known as Sendai virus (SeV) leads to

159 for RSV (n = 35), 2.6 x 10(6) copies/mL; for parainfluenza virus (n = 35), 4.9 x 10(7) copies/mL; for

160 rs mutations in the P/V gene from the canine parainfluenza virus (P/V-CPI(-)) is a potent inducer of

161 Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens

162 Parainfluenza virus (PIV) commonly infects patients foll

163 RSV F and related parainfluenza virus (PIV) F proteins are cleaved by furi

164 Parainfluenza virus (PIV) in humans is associated with b

165 Data on characteristics and outcomes of parainfluenza virus (PIV) infections in these patients a

166 Parainfluenza virus (PIV) infections may be significant

167 Parainfluenza virus (PIV) is a negative-sense single-str

168 ually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3.

169 mens), followed by human rhinovirus (17.8%); parainfluenza virus (PIV) types 1-4 (7.5%); enterovirus

170 sting for respiratory syncytial virus (RSV), parainfluenza virus (PIV), and influenza A and B, and by

171 us (HRV), respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus (InfV), metap

172 (HN, residues 37 to 56) of the paramyxovirus parainfluenza virus (PIV5), a region of the HN stalk tha

173 Parainfluenza viruses (PIVs) are one of the most common

174 significance of membrane fusion activity in parainfluenza virus replication and pathogenesis in vivo

175 e (HN) glycoprotein plays a critical role in parainfluenza virus replication.

176 ruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial virus, huma

177 roviruses, influenza virus, metapneumovirus, parainfluenza virus, rhinovirus, and respiratory syncyti

178 The parainfluenza virus simian virus 5 (SV5) is a poor induc

179 Human epithelial cells infected with the parainfluenza virus simian virus 5 (SV5) show minimal ac

180 aring the sequence of MV F with those of the parainfluenza virus SV5 and Newcastle disease virus (NDV

181 SER virus is a type 5 parainfluenza virus that does not exhibit syncytium form

182 eviously described heterotypic peptides from parainfluenza virus that potently inhibit Nipah virus in

183 Paramyxoviruses such as human parainfluenza viruses that bear inserts encoding protect

184 e protein or whole virus digests enables the parainfluenza virus to be identified and typed and for i

185 ew evidence regarding strategies employed by parainfluenza viruses to effectively circumvent respirat

186 ontact transmission, the predominant mode of parainfluenza virus transmission, was modeled accurately

187 n to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second re

188 Human parainfluenza virus type 1 (HPIV1) also causes severe pe

189 irions in two closely related viruses, human parainfluenza virus type 1 (hPIV1) and Sendai virus (SV)

190 Sendai virus (SeV) and human parainfluenza virus type 1 (hPIV1) are highly similar in

191 We evaluated a version of human parainfluenza virus type 1 (HPIV1) bearing a stabilized

192 Sendai virus (SV) and human parainfluenza virus type 1 (hPIV1) have genomes consisti

193 Human parainfluenza virus type 1 (HPIV1) is a significant caus

194 Human parainfluenza virus type 1 (HPIV1) is a significant caus

195 Human parainfluenza virus type 1 (HPIV1) is an important respi

196 Human parainfluenza virus type 1 (HPIV1) is an important respi

197 respiratory syncytial virus (RSV) and human parainfluenza virus type 1 (HPIV1) to HPIV4 infect virtu

198 onkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced

199 ned M, as was previously observed with human parainfluenza virus type 1 (hPIV1).

200 valuation of an attenuated recombinant human parainfluenza virus type 1 (rHPIV1) expressing the membr

201 Live attenuated recombinant human parainfluenza virus type 1 (rHPIV1) was investigated as

202 Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to crea

203 ons of the L polymerase of recombinant human parainfluenza virus type 1 (rHPIV1).

204 live virus vaccine, we have used the murine parainfluenza virus type 1 (Sendai virus [SV]) as a xeno

205 Hamsters immunized with a recombinant human parainfluenza virus type 1 expressing the fusion F prote

206 Human parainfluenza virus type 1 is the major cause of croup i

207 secreted from A549 cells infected with Human parainfluenza virus type 2 (HPIV-2) but not from cells i

208 Human parainfluenza virus type 2 (HPIV-2), an important pediat

209 Human parainfluenza virus type 2 (HPIV2) is the only member of

210 We sought to develop a live attenuated parainfluenza virus type 2 (PIV2) vaccine strain for use

211 t for association with V proteins from human parainfluenza virus type 2, parainfluenza virus type 5,

212 d by the V proteins of mumps virus and human parainfluenza virus type 2.

213 fever (SF) and Kansas (Ka) strains of bovine parainfluenza virus type 3 (BPIV3) are restricted in the

214 The Kansas strain of bovine parainfluenza virus type 3 (BPIV3) is 100- to 1,000-fold

215 Bovine parainfluenza virus type 3 (bPIV3) is being evaluated as

216 raminidase (HN) glycoprotein genes of bovine parainfluenza virus type 3 (BPIV3) to its restricted rep

217 to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young

218 doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3).

219 The envelope of human parainfluenza virus type 3 (HPF3) contains two viral gly

220 The envelope of human parainfluenza virus type 3 (HPF3) contains two viral gly

221 Entry and fusion of human parainfluenza virus type 3 (HPF3) require the interactio

222 Entry and fusion of human parainfluenza virus type 3 (HPF3) requires interaction o

223 erence have not been characterized for human parainfluenza virus type 3 (HPF3), and the possible role

224 inhibit the neuraminidase activity of human parainfluenza virus type 3 (HPF3).

225 ur previous observation on the role of human parainfluenza virus type 3 (HPIV 3) C protein in the tra

226 The RNA polymerase complex of human parainfluenza virus type 3 (HPIV 3), a member of the fam

227 Human parainfluenza virus type 3 (hPIV-3) is a clinically sign

228 Human parainfluenza virus type 3 (HPIV-3) is an airborne patho

229 Human parainfluenza virus type 3 (HPIV-3) is an airborne patho

230 on factor, with the cis-acting RNAs of human parainfluenza virus type 3 (HPIV3) and packaging of thes

231 valent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncy

232 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric r

233 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agent

234 SV), human metapneumovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for t

235 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and sec

236 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes

237 The genomic promoter of human parainfluenza virus type 3 (HPIV3) contains multiple cis

238 genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

239 t also the receptor interaction of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

240 plementation to follow the dynamics of human parainfluenza virus type 3 (HPIV3) HN/F pairs in living

241 We demonstrate that human parainfluenza virus type 3 (HPIV3) induces incomplete au

242 Human parainfluenza virus type 3 (HPIV3) is one of the major c

243 It was previously reported that human parainfluenza virus type 3 (HPIV3) multiplication was in

244 onnected to the stalk region of either human parainfluenza virus type 3 (HPIV3) or Nipah virus recept

245 We have analyzed the human parainfluenza virus type 3 (HPIV3) P protein and deletio

246 binant virus rHPIV3-N(B), a version of human parainfluenza virus type 3 (HPIV3) that is attenuated du

247 against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to expre

248 rt here that for three paramyxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of low

249 Human parainfluenza virus type 3 (HPIV3), a paramyxovirus, is

250 monkeys 100- to 1,000-fold compared to human parainfluenza virus type 3 (HPIV3), and the Ka strain al

251 common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector

252 encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulat

253 ing the childhood respiratory pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope

254 For human parainfluenza virus type 3 (HPIV3), the effects of speci

255 For human parainfluenza virus type 3 (HPIV3), the receptor binding

256 intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3).

257 s), Newcastle disease virus (NDV), and human parainfluenza virus type 3 (HPIV3).

258 aminidase (HN) surface glycoprotein of human parainfluenza virus type 3 (HPIV3).

259 tory syncytial virus (RSV) and one strain of parainfluenza virus type 3 (PIV-3) was determined.

260 In this study, a chimeric bovine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human P

261 Parainfluenza virus type 3 (PIV3) infection led to laryn

262 Parainfluenza virus type 3 (PIV3) infections are a major

263 Parainfluenza virus type 3 (PIV3) is major pathogen of c

264 During a phase 2 trial of parainfluenza virus type 3 (PIV3) vaccine, sequential se

265 Recombinant human parainfluenza virus type 3 (PIV3) was used as a vector t

266 r the ability to inhibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negati

267 A live attenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion

268 A live attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed prev

269 Recombinant bovine/human parainfluenza virus type 3 (rB/HPIV3), a recombinant bov

270 We constructed a human recombinant parainfluenza virus type 3 (rPIV3) that expresses enhanc

271 For human parainfluenza virus type 3 and many other paramyxoviruse

272 tial innate antiviral response against human parainfluenza virus type 3 and respiratory syncytial vir

273 s virus of the Arenaviridae family and human parainfluenza virus type 3 of the Paramyxoviridae family

274 Human parainfluenza virus type 3, a mildly cytopathic virus th

275 s of a live-attenuated vaccine candidate for parainfluenza virus type 3, an enveloped RNA virus that

276 yncytial virus, human metapneumovirus, human parainfluenza virus type 3, and measles virus, and highl

277 uses, including the childhood pathogen human parainfluenza virus type 3, enter host cells by fusion o

278 explores the binding and entry into cells of parainfluenza virus type 3, focusing on how the receptor

279 minidase abolished infection of HAE by human parainfluenza virus type 3, this treatment did not signi

280 vaccine for respiratory syncytial virus and parainfluenza virus type 3, two major causes of severe r

281 viruses, including the human pathogen human parainfluenza virus type 3, yet these compounds by thems

282 protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that express

283 lymphocytic choriomeningitis virus and human parainfluenza virus type 3.

284 ion, which was 40-fold lower than that of WT parainfluenza virus type 3.

285 ction of interferon (IFN) alpha/beta against parainfluenza virus type 5 (PIV5), selectively inhibitin

286 teins from human parainfluenza virus type 2, parainfluenza virus type 5, measles virus, mumps virus,

287 We investigated the binding of human parainfluenza virus types 1 and 3 (hPIV1 and hPIV3, resp

288 luding influenza virus A, influenza virus B, parainfluenza virus types 1 and 3, respiratory syncytial

289 tial virus [RSV], influenza A and B viruses, parainfluenza virus types 1 to 3, and adenovirus) was co

290 A and B and human metapneumovirus, and (iii) parainfluenza virus types 1 to 4.

291 virus (RSV), influenza virus type A (FluA), parainfluenza virus types 1, 2, and 3 (PIV1, PIV2, and P

292 criptase (RT)-PCR assay for the detection of parainfluenza virus types 1, 2, and 3, respiratory syncy

293 iratory syncytial viruses A and B; and human parainfluenza virus types 1, 2, and 3.

294 iruses, including influenza A and B viruses, parainfluenza virus types 1-3, respiratory syncytial vir

295 ed negative for respiratory syncytial virus, parainfluenza viruses (types 1-3), influenza A and B vir

296 act of respiratory syncytial virus (RSV) and parainfluenza virus URIs on the frequency of AOM caused

297 C28a HN is the first parainfluenza virus variant found so far to be specifica

298 pared to tissue culture for the detection of parainfluenza virus were 100, 95.8, 19.0, and 100%, resp

299 naturally occurring SV5 variant Wake Forest parainfluenza virus (WF-PIV) activates the synthesis of

300 so showed that extraction will be needed for parainfluenza virus, which was only identified correctly